Assessment of Coronary Plaque Composition

Overview

About this study

The investigators hypothesis is that local activation of the endogenous Lp-PLA2 plays an integral role in early atherosclerosis, and contributes to the mechanism of coronary endothelial dysfunction and to the structural and mechanical properties that characterize plaque vulnerability. Thus, our study will characterize prospectively the correlation between the functional and structural vascular wall properties, and the activity of the Lp-PLA2 pathway.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Study closed to enrollment

Inclusion Criteria

patients age > 18 years and < 85 years
referred to our cardiac catheterization laboratory for coronary vasomotion testing- subsequently found to have coronary endothelial dysfunction.

Exclusion Criteria

heart failure ejection fraction <40%,
unstable angina
myocardial infarction or angioplasty within 6 months prior to entry into the study
use of investigational agents within 1 month of entry into the study
patients who require treatment with positive inotropic agents other than digoxin during the study
patients with cerebrovascular accident within 6 months prior to entry the study
significant endocrine, hepatic or renal, disorders, local or systemic infectious disease within 4 weeks prior to entry into study
pregnancy or lactation
mental instability

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator Amir Lerman, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

Amir Lerman, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials